Joel Greenblatt’s Lexicon Pharmaceuticals LXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,627
Closed -$32.7K – 1923
2026
Q2
$32.7K Buy
+13,627
New +$26.5K ﹤0.01% 1788
2017
Q1
– Sell
-27,102
Closed -$375K – 1059
2016
Q4
$375K Sell
27,102
-20,533
-43% -$329K ﹤0.01% 771
2016
Q3
$861K Sell
47,635
-247,459
-84% -$3.98M 0.01% 623
2016
Q2
$4.24M Buy
295,094
+105,777
+56% +$1.43M 0.05% 411
2016
Q1
$2.26M Buy
+189,317
New +$1.98M 0.03% 562
2015
Q2
– Sell
-10,509
Closed -$69K – 984
2015
Q1
$69K Buy
+10,509
New +$71.8K ﹤0.01% 888

Other funds holding LXRX

Joel Greenblatt's LXRX Position: Q3 2026 in Review

Joel Greenblatt sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2026, closing a stake of 13,627 shares — an estimated $32.7K sold.

Joel Greenblatt first reported a position in LXRX in Q1 2015 and held it in 6 quarters. The position peaked at $4.24M in Q2 2016. 157 funds tracked by Wall St. Rank hold LXRX as of Q3 2026.

  • Joel Greenblatt reported no remaining Lexicon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Joel Greenblatt sold 13,627 Lexicon Pharmaceuticals shares in Q3 2026, an estimated $32.7K.
  • Joel Greenblatt first reported a position in Lexicon Pharmaceuticals in Q1 2015 and held it in 6 quarters.
  • Joel Greenblatt's Lexicon Pharmaceuticals position peaked at $4.24M in Q2 2016.
  • 157 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.